Filter By Category
Archives
Share on -
ANVATABART OPADOTIN
Generic Name: ANVATABART OPADOTIN
ABSTRACT -
Ansornitinib (ANG-3070) is an investigational, orally administered multi-target receptor tyrosine kinase inhibitor developed for antifibrotic activity. Reported targets include discoidin domain receptors and platelet-derived growth factor receptors, with additional activity against vascular endothelial growth factor receptor pathways. Clinical development has focused on chronic kidney and fibrotic disorders.
DOSAGE –
-
- No approved standard dosage has been established. Oral dose, schedule, treatment duration, food instructions, and dose modifications must be taken only from the applicable clinical-trial protocol. Animal-study doses are not clinically interchangeable and must not be used for human treatment.
SIDE EFFECTS –
- Dry eye, blurred vision, keratopathy, or other ocular toxicity
- Fatigue or weakness
- Nausea, vomiting, or reduced appetite
- Raised liver enzymes
- Anaemia, neutropenia, or thrombocytopenia
- Interstitial lung disease or pneumonitis
ALLRGIC RACTIONS–
(These symptoms may indicate a serious allergic or infusion reaction and require medical attention.)
-
- Infusion-related flushing, fever, chills, or rash
- Hives or generalized itching
- Face or throat swelling
- Bronchospasm, breathing difficulty, or anaphylaxis
DRUG INTERACTIONS –
-
- Formal drug-interaction studies are limited
- Other pulmonary-toxic therapies may increase pneumonitis risk
- Other ocular-toxic medicines may complicate eye toxicity
- Myelosuppressive or hepatotoxic anticancer agents may increase overlapping toxicity
PRECAUTIONS –
- Baseline and periodic ophthalmic assessment may be required
- Monitor for new cough, breathlessness, fever, or reduced oxygen saturation
- Check blood counts, liver tests, and cardiac status according to protocol
- Use effective contraception and follow protocol-specific pregnancy precautions
WARNINGS –
- Potentially serious interstitial lung disease requires immediate evaluation
- Ocular toxicity may require dose delay, reduction, treatment, or discontinuation
- Infusion reactions and severe cytopenias require specialist management
Share on -
. Developed by